Hematological Malignancies

Although the R-CHOP regimen effectively cures 60-70% of patients, 30-40% of patients relapse or develop resistance, highlighting the need for new biomarkers to improve prognosis and therapeutic strategies...Our findings suggest that the SREBF2-ACOT7 axis plays a critical role in DLBCL by promoting tumor cell growth, invasion, and survival. ACOT7 could serve as a potential prognostic biomarker and therapeutic target for DLBCL, providing new insights into the molecular mechanisms of this aggressive lymphoma.

P=N/A, N=200, Recruiting, Mayo Clinic | Trial primary completion date: Dec 2026 --> Dec 2027

P2, N=20, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Feb 2030 | Trial primary completion date: Dec 2027 --> Feb 2030

P1, N=54, Active, not recruiting, Fate Therapeutics | Trial primary completion date: Sep 2024 --> Jun 2025

P1/2, N=28, Active, not recruiting, University of Colorado, Denver | Trial primary completion date: Aug 2026 --> Oct 2025

P2, N=39, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

P2, N=37, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Our new unique mouse model will allow further studies of the effects of Trp53 nonsense mutation in a multi-organ system and serve as a model for the Li-Fraumeni syndrome (LFS). It will also be valuable for preclinical evaluation of novel therapeutic strategies for targeting TP53 nonsense mutations in cancer.

The tumor-to-bone marrow absorbed dose ratio was in the same range for [161Tb]Tb-DOTA-LM3 as for [177Lu]Lu-DOTATOC. The administration of 1 GBq of [161Tb]Tb-DOTA-LM3 was safe for all patients, without relevant adverse events.

Collectively, these data define a molecular continuum from chronic gastritis to GC and highlight LIFR, IL10RB, SERPINE1 and HGF as pivotal biological macromolecules and candidate therapeutic targets. The repurposing potential of anti-inflammatory agents, particularly rofecoxib and nabumetone, suggests a feasible strategy to intercept the gastritis-carcinoma sequence.

All the data presented in the manuscript are supported by diverse experimental approaches, including transcriptional analyses, functional in vitro assays (migration, invasion, apoptosis), gain- and loss-of-function experiments, luciferase reporter assays, and in vivo xenograft models, further validating the miRNA-RKIP axis involved in the progression of multiple tumors. In conclusion, this review provides an integrated view of the complex post-transcriptional network governing RKIP regulation in cancer, underscoring the potential of targeting RKIP-associated non-coding RNA axes for innovative therapeutic strategies aimed at halting tumor progression and overcoming treatment resistance.

In patients with Richter transformation, epcoritamab monotherapy showed clinically meaningful antitumour activity, although the investigator-assessed overall response rate was below the alternative hypothesis of 50%, with a safety profile consistent with previous studies. These findings support further investigation of epcoritamab as a potential treatment option for patients with Richter transformation.